Publish in this journal
Journal Information
Vol. 220. Issue 7.
Pages 457 (October 2020)
Vol. 220. Issue 7.
Pages 457 (October 2020)
Correspondence
DOI: 10.1016/j.rceng.2020.04.007
Full text access
COVID-19 and Argumentum ad ignorantiam or “not everything goes”
COVID-19 y Argumentum ad ignorantiam o «no todo vale»
Visits
...
M.L. López Reboiro, C. Sardiña González, J. López Castro
Corresponding author
jlcastro126@hotmail.com

Corresponding author.
Servicio de Medicina Interna, Hospital Público de Monforte, Lugo, Spain
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text
Dear Director,

After having read with interest the letter by Dr. Abril López de Medrano et al.,1 which we wholeheartedly endorse, we would like to raise an alarm about a curious process of scientific thinking that, to our understanding, is happening in a generalized manner in the global management of treatment against COVID-19. It is the so-called Argumentum ad ignorantiam fallacy, which consists of thinking that “lack of awareness of evidence contrary to an idea that we support counts as evidence in its favor.” Nothing is further from the truth, and even more so given the capacity of generating multiple trial-and-error tests with unpredictable consequences, particularly in a disease that we unfortunately still know very little about.

Let’s look at an example: a recently published preclinical study observed that the anthelmintic ivermectin achieves inhibition of SARS-CoV-2 replication in vitro in 48 h.2 As no evidence against it has been published to date, the possible theoretical benefits of this drug in humans are to be expected. Nevertheless, if we review the work in detail, it is observed that the dose of ivermectin used in vitro is 5 µM. To achieve this concentration in a human being, oral administration on the order of 1000–1200 mg of ivermectin would be needed. According to the drug's technical datasheet, the dose tested in humans (healthy volunteers) is around 100–120 mg (single dose) and severe side effects due to intoxication include ataxia and seizures.3 For this reason, it seems clear that it would not be possible to use this drug to treat SARS-CoV-2 in humans, as the levels required for it to be effective in humans would very probably also be highly toxic.

Let’s suppose that this drug had been tested at the usual doses approved by the Spanish Agency of Medicines and Medical Devices (AEMPS, for its initials in Spanish) (thus below the therapeutic range for COVID-19) in a health center that had low mortality rates for the disease. In this scenario, it could have falsely been assumed that ivermectin played a decisive role in curing these patients. This is not so, as adequate therapeutic levels in the blood would not have been achieved.

Therefore, we must be on the alert to publications on “sensationalist” therapies supported by small case series (ozone therapy, vitamin D supplements, etc.) and, sometimes, by the doubtful methodology that, supported by the principal of Argumentum ad ignorantiam, promise fantasies of cures for COVID-19 disease.

References
[1]
V Abril López de Medrano, EM de Lucas, M. Salavert Lletí.
Tomar o no tomar «decisiones en caliente» respecto al tratamiento de la infeccion por SARS-CoV-2.
[2]
L. Caly, J.D. Druce, M.G. Catton, D.A. Jans, K.M. Wagstaff.
The FDA approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro.
[3]
Ficha técnica de Stromectol 3 mg. Lab. MSD.

Please cite this article as: López Reboiro ML, Sardiña González C, López Castro J. COVID-19 y Argumentum ad ignorantiam o «no todo vale». Rev Clin Esp. 2020;220:457.

Copyright © 2020. Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI)
Idiomas
Revista Clínica Española (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.